These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10350035)

  • 21. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
    Bizouard P; Vandel S; Kantelip JP
    Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
    [No Abstract]   [Full Text] [Related]  

  • 22. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.
    Jardemark KE; Liang X; Arvanov V; Wang RY
    Neuroscience; 2000; 100(1):1-9. PubMed ID: 10996453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 25. [Olanzapine (Zyprexa)].
    Sahebjam M; Serra E
    Presse Med; 2000 Dec; 29(38):2106-8. PubMed ID: 11147054
    [No Abstract]   [Full Text] [Related]  

  • 26. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
    Hanel RA; Sandmann MC; Kranich M; De Bittencourt PR
    Arq Neuropsiquiatr; 1998 Dec; 56(4):833-7. PubMed ID: 10029891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Life threatening neuroleptic malignant syndrome due to olanzapine].
    Kopf A; Köster J; Schulz A; Krömker H; Becker T
    Psychiatr Prax; 2003 Jul; 30(5):279-82. PubMed ID: 12872187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine for the treatment of tardive dyskinesia.
    Almeida OP
    J Clin Psychiatry; 1998 Jul; 59(7):380-1. PubMed ID: 9714267
    [No Abstract]   [Full Text] [Related]  

  • 31. Opposite effects of olanzapine and haloperidol in rat ultrasonic vocalization test.
    Siemiatkowski M; Maciejak P; Sienkiewicz-Jarosz H; Członkowska AI; Szyndler J; Gryczyńska A; Płaźnik A
    Pol J Pharmacol; 2001; 53(6):669-73. PubMed ID: 11985344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
    Berk M; Brook S; Trandafir AI
    Int Clin Psychopharmacol; 1999 May; 14(3):177-80. PubMed ID: 10435771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic olanzapine treatment on striatal synaptic organization.
    Roberts RC
    Synapse; 2001 Jan; 39(1):8-15. PubMed ID: 11071704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
    Agarwal V; Kumar P
    J Clin Psychiatry; 2001 Apr; 62(4):298-9. PubMed ID: 11379849
    [No Abstract]   [Full Text] [Related]  

  • 39. Conventional psychotropic-induced tremor extinguished by olanzapine.
    Strauss AJ; Bailey RK; Dralle PW; Eschmann AJ; Wagner RB
    Am J Psychiatry; 1998 Aug; 155(8):1132. PubMed ID: 9699709
    [No Abstract]   [Full Text] [Related]  

  • 40. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.